This content is only available within our institutional offering.
10 Oct 2019
UCB: Ra Pharma acquisition: a new sunrise for UCB? | NEUTRAL | EUR69(+9%)
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
UCB: Ra Pharma acquisition: a new sunrise for UCB? | NEUTRAL | EUR69(+9%)
UCB S.A. (UCB:WBO) | 0 0 1.1% | Mkt Cap: 13,141m
- Published:
10 Oct 2019 -
Author:
Jean-Jacques Le Fur -
Pages:
5
UCB - NEUTRAL | EUR69(+9%)
Ra Pharma acquisition: a new sunrise for UCB?
An acquisition to enter the rare disease area
Positive phase II results in MG
A dilutive but strategic acquisition